L-Methylfolate in Diabetic Peripheral Neuropathy: A Narrative Review

Area of Science:

• Neurology
• Metabolic Disorders
• Nutritional Science

Background:

• Diabetic peripheral neuropathy (DPN) is a common complication of diabetes mellitus.
• Current treatments for DPN primarily manage symptoms, not underlying causes.
• The C677T methylenetetrahydrofolate reductase gene variant is associated with increased DPN risk.

Purpose of the Study:

• To review the mechanistic effects and clinical data supporting L-methylfolate calcium (LMF) for DPN management.
• To explore LMF's role in addressing DPN pathophysiology beyond symptomatic relief.

Main Methods:

• Literature search of preclinical and clinical studies on LMF and DPN (2010-2023).
• Searches included terms: folate, LMF, diabetes, neuropathy, neuropathic pain, genetic polymorphisms.
• Focused on studies evaluating LMF's impact on DPN pathophysiology and clinical outcomes.

Main Results:

• LMF demonstrated significant beneficial effects on DPN, addressing underlying pathophysiology.
• Studies showed LMF improves DPN symptoms and patient quality of life.
• LMF was associated with minimal adverse effects in clinical trials.

Conclusions:

• L-methylfolate calcium (LMF) can treat the underlying causes of DPN.
• LMF provides long-lasting symptomatic relief for DPN.
• LMF represents a promising therapeutic option for DPN management.